Abaxis ( ABAX) upgraded at Suntrust Robinson Humphrey from Neutral to Buy. $28 price target. Company has addressed a lot of its near-term issues. Stock is already up 20% from lows, but still has upside potential. BankUnited Financial ( BKUNA) downgraded at Keefe, Bruyette & Woods to Market Perform. $17 price target. Estimates also cut, to reflect the company's new guidance for non-performing assets. Ciena ( CIEN) upgraded at UBS to Neutral rating from Sell. Price target lifts to $49 from $41 and 2008 EPS estimates upped to $1.76 from $1.58. Ciena numbers raised at Jefferies. Price target lifts to $42 from $34 and FY 2008 EPS estimates jump to $1.65 from $1.45. Reiterates Hold rating. Cooper Cos. ( COO) downgraded at Bear Stearns from Peer Perform to Underperform. $53 price target. Stock is already pricing in best-case scenario for sales growth, and margin expansion could come in below expectations. Endo Pharma ( ENDP) downgraded at Jefferies to Hold rating from Buy. Price target slashed to $31 from $37 while 2008 EPS estimates hold at $2.17. Esterline ( ESL) downgraded at UBS to Neutal rating from Buy. Price target lifts to $62 from $58 while 2008 EPS estimates holds at $3.15. Fiserv ( FISV) upgraded at JP Morgan to Overweight. Checkfree deal should enhance growth and give the company significant cross-selling opportunities.